TLDR:
- Gilead Sciences secures $210M from Abingworth for Trodelvy trials
- Abingworth will offer funding to support select clinical studies of Trodelvy in non-small cell lung cancer
In a unique collaboration between Big Pharma and venture capital, Gilead Sciences has secured $210 million from Abingworth to fund clinical trials for Trodelvy, an antibody-drug conjugate. This funding will support select clinical studies of Trodelvy in non-small cell lung cancer, a key area of focus for the California pharma company. The agreement includes a fixed payment upon regulatory approval in a specified indication, as well as royalties based on Trodelvy’s U.S. sales within NSCLC.
The funding comes at a critical time for Trodelvy, as the drug recently faced a setback in a phase 3 trial for metastatic NSCLC. While the study did not meet its primary endpoint, Gilead remains confident in Trodelvy’s potential based on overall survival improvements in certain patient subgroups.
In addition to the financial support, the deal between Abingworth and Gilead also includes a non-monetary collaboration, where Gilead will form a clinical development joint steering committee with Launch Therapeutics, an Abingworth/Carlyle portfolio company. This collaboration signifies a unique approach to funding and clinical development within the biopharma industry.
